Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis

VIEWS: 822 PAGES: 125

Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis and Psoriatic Arthritis Summary GBI Research’s new report, “Arthritis Therapeutics Market to 2016 - Biologics Revolutionize Treatment of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Scope The scope of this report includes: - Annualized market data for the arthritis therapeutics market from 2001 to 2009, forecast forward to 2016. - Market characterization of the arthritis therapeutics market, including market size, annual cost of therapy and treatment usage patterns. - Key drivers and barriers that have a significant impact on the market. - Coverage of pipeline molecules in various phases of drug development. . - Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global arthritis therapeutics market. Reasons to buy The report will enhance your decision making capability. It will allow you to - Align your product portfolio to the markets with high growth potential. - Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth. - Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety. - Develop key stra

More Info
									              Arthritis Therapeutics Market to 2016 - Biologics
            Revolutionize Treatment of Rheumatoid Arthritis and
                              Psoriatic Arthritis
 Reference Code: GBIHC042MR                                                                                                     Publication Date: OCT 2010

  Efficacious results from
  biologics have increased             High Growth Rate and Increasing Use of Biologics Has Made Arthritis Therapeutics Market
  its demand for arthritis             Attractive
  therapeutics market,                 The global arthritis therapeutics market is a fast growing market, with arthritis considered to be the
  accounting the sales for             prime factor for chronic disability in the workforce .In 2009; the global arthritis therapeutics market
  more than 80% out of                 was worth $18.4 billion, which is forecast to grow to $30 billion by 2016, showing a growth rate of
  $18.4 billion in 2009.               7.3% between 2009 and 2016.

                                         Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2001-2016

                                                            35



                                                            30

                                                                                                                     CAGR(2009-2016): 7.3%

                                                            25
                                            Revenue ($bn)




                                                            20           CAGR(2001-2009): 7.4%




                                                            15



                                                            10



                                                             5



                                                             0
                                                                 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016


                                         Source: GBI Research




                                       The arthritis therapeutics market has been growing at a fast pace over the past few years, and is
                                       expected to accelerate in the coming years. However, the market will face a marginal decline in
                                       revenues due to the patent expiries of the biggest selling drugs, including Celebrex (celecoxib) and
                                       Humira (adalimumab), between 2009 and 2016. However, the launch of blockbuster drugs such as
                                       Vicodin and Simponi along with the presence of many potential biologics in late stage development
                                       will offset the decline in revenues. In addition, the increase in the incidence rates of osteoarthritis,
                                       Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) will trigger growth in the global arthritis
                                       therapeutics market. As a result, the market will continue to remain fast growing, thereby attracting
                                       the activities of major pharmaceutical companies.




Arthritis Therapeutics Market to 2016 - Biologics Revolutionize                                                             GBIHC042MR / Published OCT 2010
Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
                                                                                                                                                         Page 1
                                                                                          © GBI Research. This is a licensed product and is not to be photocopied
                                       Strong Pipeline and the Entry of New Players Will Intensify the Competition
                                       The arthritis therapeutics market has a strong pipeline base that will support the growth of this
                                       market thereby attracting many pharmaceutical and biotechnological companies. Major
                                       pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are active in their
                                       pipeline for arthritis. One of the major activities is the development of biologics as a part of new
                                       treatment options. There are also some disease modifiers in the pipeline related to osteoarthritis
                                       that are expected to enter the market in 2018. The entry of these disease modifiers will boost the
                                       osteoarthritis therapeutics market, thereby bringing about further rises in the arthritis therapeutics
                                       market in the coming years. The rapid entry of new players and the highly active pipeline will
                                       intensify competition.

                                         Arthritis Therapeutics Market, Global, Research and Development Pipeline, %, September
                                         2010


                                                                                                 Discovery
                                                                              Phase III             8%
                                                                                15%



                                                                                                                Preclinical
                                                                                                                  25%




                                                                   Phase II
                                                                    32%



                                                                                                      Phase I
                                                                                                       20%


                                         Source: GBI Research




                                       The Top Four Companies Contribute More Than 80% to the Global Arthritis Market
                                       The global arthritis therapeutics market is dominated by four major pharmaceutical companies that
                                       account for more than 80% of the total market. The major market share is occupied by Abbott [with
                                       Humira (adalimumab)], the Amgen [with Enbrel (etanercept)], Johnson & Johnson [with
                                       Remicade(infliximab)] and Pfizer (with Celebrex). The presence of various large as well as small
                                       pharmaceutical companies makes this market strong in terms of competition. However, the
                                       presence of blockbuster drugs has made these four companies the dominant players in this market.
                                       This shows that the Arthritis therapeutics market is highly concentrated, leaving less than 20% of
                                       the market open for other players to operate.
                                       Strategic Consolidations Have Led To the Entry of New Players into the Arthritis
                                       Therapeutics Market
                                       In the past seven years, many pharmaceutical companies have improved their product profiles with
                                       respect to the arthritis therapeutics market. This is due to prominent deals with the aim of
                                       introducing new products with better efficacy and safety profiles into the market. The acquisitions of
                                       Medarex by Bristol-Myers Squibb, Wyeth by Pfizer and Daiichi Sankyo by Ranbaxy laboratories
                                       have been the major acquisitions affecting the arthritis therapeutics market. Under licensing
                                       agreements, the highest valued agreement was the license given by Alder Biopharmaceuticals to
                                       Bristol-Myers Squibb for their RA molecule ALD518, currently in Phase II of development. In
                                       addition, companies such as Pfizer, Abbott, Merck and Novartis have the potential to expand their
                                       market coverage due to these consolidations, making the competition even more intense.
                                       These strategic consolidations will help both the acquirer and licensee companies to diversify their
                                       profiles by entering into the arthritis therapeutics market, which will in turn make the arthritis
                                       therapeutics market more vibrant. These consolidations will also help the companies to generate
                                       revenue, thereby increasing the total revenue of the global arthritis therapeutics market.


Arthritis Therapeutics Market to 2016 - Biologics Revolutionize                                                  GBIHC042MR / Published OCT 2010
Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
                                                                                                                                             Page 2
                                                                              © GBI Research. This is a licensed product and is not to be photocopied
                                       1         Table of Contents
                                       1   Table of Contents ........................................................................................................................ 3
                                           1.1     List of Tables..................................................................................................................... 5
                                           1.2     List of Figures ................................................................................................................... 7
                                       2   Arthritis Therapeutics Market to 2016: Introduction ..................................................................... 9
                                           2.1     GBI Research Report Guidance ....................................................................................... 9
                                       3   Arthritis Therapeutics Market to 2016: Market Overview ........................................................... 10
                                           3.1     Introduction ..................................................................................................................... 10
                                           3.2     Revenue Forecasts for the Global Arthritis Therapeutics Market.................................... 10
                                              3.2.1     Revenue .................................................................................................................. 10
                                              3.2.2     Annual Cost of Treatment (ACT) ............................................................................. 12
                                              3.2.3     Treatment Usage Patterns ...................................................................................... 13
                                       4   Arthritis Therapeutics Market to 2016: Geographical Landscape .............................................. 19
                                           4.1     Revenue Analysis by Geography.................................................................................... 19
                                           4.2     The US............................................................................................................................ 21
                                              4.2.1     Revenue .................................................................................................................. 21
                                              4.2.2     Annual Cost of Treatment........................................................................................ 23
                                              4.2.3     Treatment Usage Patterns ...................................................................................... 25
                                           4.3     Top Five Countries of Europe ......................................................................................... 31
                                              4.3.1     Revenue .................................................................................................................. 31
                                              4.3.2     Annual Cost of Treatment........................................................................................ 32
                                              4.3.3     Treatment Usage Patterns ...................................................................................... 33
                                           4.4     Japan .............................................................................................................................. 39
                                              4.4.1     Revenue .................................................................................................................. 39
                                              4.4.2     Annual Cost of Treatment........................................................................................ 40
                                              4.4.3     Treatment Usage Patterns ...................................................................................... 41
                                       5   Arthritis Therapeutics Market to 2016: Therapeutic Landscape ................................................ 47
                                           5.1     Osteoarthritis Therapeutics Market ................................................................................. 47
                                              5.1.1     Introduction.............................................................................................................. 47
                                              5.1.2     Revenue .................................................................................................................. 47
                                              5.1.3     Annual Cost of Treatment........................................................................................ 49
                                              5.1.4     Treatment Usage Patterns ...................................................................................... 50
                                           5.2     Drivers and Barriers for the Osteoarthritis Therapeutics Market ..................................... 56
                                              5.2.1     Drivers for the Osteoarthritis Therapeutics Market .................................................. 56
                                              5.2.2     Barriers for the Osteoarthritis Therapeutics Market ................................................. 57
                                           5.3     Opportunity and Unmet Need ......................................................................................... 57
                                           5.4     Rheumatoid Arthritis Therapeutics Market ...................................................................... 57
                                              5.4.1     Introduction.............................................................................................................. 57
                                              5.4.2     Revenue .................................................................................................................. 58
                                              5.4.3     Annual Cost of Treatment........................................................................................ 59
                                              5.4.4     Treatment Usage Patterns ...................................................................................... 60
                                           5.5     Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market .......................... 66
                                              5.5.1     Drivers for the Rheumatoid Arthritis Therapeutics Market ....................................... 66
                                              5.5.2     Barriers for the Rheumatoid Arthritis Therapeutics Market ...................................... 67
                                           5.6     Opportunity and Unmet Need ......................................................................................... 67
                                           5.7     Psoriatic Arthritis Therapeutics Market ........................................................................... 67
                                              5.7.1     Introduction.............................................................................................................. 67
                                              5.7.2     Revenue .................................................................................................................. 68
                                              5.7.3     Annual Cost of Treatment........................................................................................ 69
                                              5.7.4     Treatment Usage Patterns ...................................................................................... 70
                                           5.8     Drivers and Barriers for the Psoriatic Arthritis Therapeutics Market................................ 76
                                              5.8.1     Drivers for the Psoriatic Arthritis Therapeutics Market............................................. 76
                                              5.8.2     Barriers for the Psoriatic Arthritis Therapeutics Market ........................................... 77

Arthritis Therapeutics Market to 2016 - Biologics Revolutionize                                                                         GBIHC042MR / Published OCT 2010
Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
                                                                                                                                                                                Page 3
                                                                                          © GBI Research. This is a licensed product and is not to be photocopied
                                         5.9     Opportunity and Unmet Need ......................................................................................... 77
                                       6 Arthritis Therapeutics Market to 2016: Pipeline Analysis........................................................... 78
                                         6.1     Introduction ..................................................................................................................... 78
                                            6.1.1     Research and Development Pipeline – Osteoarthritis ............................................. 79
                                            6.1.2     Research and Development Pipeline – Rheumatoid Arthritis .................................. 85
                                            6.1.3      Research and Development Pipeline – Psoriatic Arthritis....................................... 95
                                         6.2     Profiles of Promising Drugs in the Arthritis Therapeutics Market .................................... 97
                                            6.2.1     CG5503 ................................................................................................................... 97
                                            6.2.2     Vicodin CR............................................................................................................... 97
                                            6.2.3     T-614 (iguratimod) ................................................................................................... 98
                                            6.2.4     AIN457 .................................................................................................................... 99
                                            6.2.5     Alefacept + Methotrexate......................................................................................... 99
                                            6.2.6     Apremilast ............................................................................................................. 100
                                            6.2.7     Cimzia ................................................................................................................... 101
                                            6.2.8     CP-690550 ............................................................................................................ 102
                                            6.2.9     Fludarabine............................................................................................................ 103
                                            6.2.10 PG102 ................................................................................................................... 103
                                            6.2.11 Rituxan + Methotrexate ......................................................................................... 104
                                       7 Arthritis Therapeutics Market to 2016: Competitive Landscape .............................................. 106
                                         7.1     Evolving Competitive Landscape .................................................................................. 106
                                            7.1.1     Major Players......................................................................................................... 106
                                         7.2     Market Share Analysis .................................................................................................. 107
                                         7.3     Competitive Profiling ..................................................................................................... 107
                                            7.3.1     Abbott Laboratories ............................................................................................... 107
                                            7.3.2     Amgen Inc. ............................................................................................................ 109
                                            7.3.3     Johnson & Johnson ............................................................................................... 110
                                            7.3.4     Pfizer ..................................................................................................................... 111
                                            7.3.5     Novartis AG ........................................................................................................... 113
                                            7.3.6     Eli Lilly and Company ............................................................................................ 114
                                            7.3.7     Boehringer Ingelheim GmbH ................................................................................. 115
                                            7.3.8     Lupin...................................................................................................................... 116
                                       8 Arthritis Therapeutics Market to 2016: M&A Landscape.......................................................... 117
                                         8.1     Mergers and Acquisitions.............................................................................................. 117
                                            8.1.1     Pfizer Acquires Wyeth ........................................................................................... 117
                                            8.1.2     Cephalon Acquires Arana Therapeutics ................................................................ 118
                                            8.1.3     Aspen Pharmacare Acquires Sigma Pharmaceuticals .......................................... 118
                                            8.1.4     Deals by Geography.............................................................................................. 118
                                            8.1.5     Deals by Value ...................................................................................................... 119
                                       9 Arthritis Therapeutics Market to 2016: Appendix ..................................................................... 120
                                         9.1     Market Definitions ......................................................................................................... 120
                                         9.2     Abbreviations ................................................................................................................ 120
                                         9.3     Research Methodology ................................................................................................. 121
                                            9.3.1     Coverage ............................................................................................................... 121
                                            9.3.2     Secondary Research ............................................................................................. 121
                                            9.3.3     Primary Research.................................................................................................. 122
                                            9.3.4     Forecasts............................................................................................................... 122
                                            9.3.5     Expert Panel Validation ......................................................................................... 124
                                         9.4     Contact Us .................................................................................................................... 125
                                         9.5     Disclaimer ..................................................................................................................... 125
                                         9.6     Sources......................................................................................................................... 125




Arthritis Therapeutics Market to 2016 - Biologics Revolutionize                                                                      GBIHC042MR / Published OCT 2010
Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
                                                                                                                                                                            Page 4
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                       1.1      List of Tables
                                       Table 1:     Arthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 ................................ 11
                                       Table 2:     Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016................ 11
                                       Table 3:     Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009 .......... 13
                                       Table 4:     Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 .......... 13
                                       Table 5:     Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-2009
                                                    ....................................................................................................................................... 14
                                       Table 6:     Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-2016
                                                    ....................................................................................................................................... 14
                                       Table 7:     Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2001-
                                                    2009 ............................................................................................................................... 19
                                       Table 8:     Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2009-
                                                    2016 ............................................................................................................................... 20
                                       Table 9:     Arthritis Therapeutics Market, The US, Revenue ($bn), 2001-2009............................... 22
                                       Table 10:     Arthritis Therapeutics Market, The US, Revenue Forecasts ($bn), 2009-2016............. 22
                                       Table 11:    Arthritis Therapeutics Market, The US, Annual Cost of Treatment($), 2001-2009 ......... 24
                                       Table 12:    Arthritis Therapeutics Market, The US, Annual Cost of Treatment($), 2009-2016 ......... 24
                                       Table 13:    Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2001-2009
                                                    ....................................................................................................................................... 26
                                       Table 14:    Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2009-2016
                                                    ....................................................................................................................................... 26
                                       Table 15:    Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2001-2009....... 31
                                       Table 16:    Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2009-
                                                    2016 ............................................................................................................................... 31
                                       Table 17:    Arthritis Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment
                                                    ($), 2001-2009................................................................................................................ 32
                                       Table 18:    Arthritis Therapeutics Market, Top Five Countries in the EU, Annual Cost of Treatment
                                                    ($), 2009-2016................................................................................................................ 33
                                       Table 19:    Arthritis Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns
                                                    (millions), 2001-2009...................................................................................................... 34
                                       Table 20:    Arthritis Therapeutics Market, Top Five Countries in the EU, Treatment Usage Patterns
                                                    (millions), 2009-2016...................................................................................................... 34
                                       Table 21:    Arthritis Therapeutics Market, Japan, Revenue ($bn), 2001-2009 ................................. 39
                                       Table 22:    Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2009-2016 .................. 39
                                       Table 23:    Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2001-2009 .......... 40
                                       Table 24:    Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2009-2016 .......... 40
                                       Table 25:    Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2001-200942
                                       Table 26:    Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2009-201642
                                       Table 27:    Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 ....................... 48
                                       Table 28:    Osteoarthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2009-2016 ........ 48
                                       Table 29:    Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2009
                                                    ....................................................................................................................................... 49
                                       Table 30:    Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2009-2016 49
                                       Table 31:    Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2001-
                                                    2009 ............................................................................................................................... 51
                                       Table 32:    Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009-
                                                    2016 ............................................................................................................................... 52
                                       Table 33:    Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2001-2009 ............ 58
                                       Table 34:    Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2009-2016
                                                    ....................................................................................................................................... 58
                                       Table 35:    Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-
                                                    2009 ............................................................................................................................... 59
                                       Table 36:    Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment($), 2009-
                                                    2016 ............................................................................................................................... 60
                                       Table 37:    Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions),
                                                    2001-2009 ...................................................................................................................... 61
                                       Table 38:    Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions),
                                                    2009-2016 ...................................................................................................................... 62
                                       Table 39:    Psoriatic Arthritis Therapeutics Market, Global, Revenue ($m), 2001-2009................... 68
                                       Table 40:    Psoriatic Arthritis Therapeutics Market, Global, Revenue Forecast ($m), 2009-2016... 
								
To top